BioLife Solutions Welcomes Tony J. Hunt to Its Board of Directors for Enhanced Growth Strategy

BioLife Solutions Welcomes Tony J. Hunt to Its Board of Directors

BioLife Solutions, Inc. (Nasdaq: BLFS), a prominent player in the bioproduction sector, has announced that Tony J. Hunt, the Executive Chairman of Repligen Corporation (Nasdaq: RGEN), will be joining its Board of Directors effective January 2, 2025. This strategic addition will increase the board's membership to six.

Tony Hunt is known for his extensive experience in bioprocessing innovation and comes to BioLife with a wealth of knowledge and a successful track record in the life sciences industry. Roderick de Greef, Chairman and CEO of BioLife, expressed excitement over Hunt's appointment, acknowledging his reputation and accomplishments in the sector. De Greef stated, “Tony is highly respected in the life sciences industry with decades of accomplishments, and it is an honor he has agreed to serve on our board.”

Hunt's previous role as the CEO of Repligen Corporation saw him leading the company through substantial growth, driven by strategic acquisitions and a robust product development approach. His expertise in guiding firms within the cell and gene therapy (CGT) market will be invaluable as BioLife looks to expand its operational scope and enhance its offerings in bioproduction workflows.

“I am excited to be joining BioLife at a critical time in their evolution,” said Tony Hunt regarding his new role. He noted the significant progress the BioLife team has made in reassessing and prioritizing their portfolio, particularly their focus on cell processing solutions in CGT. Hunt is looking forward to collaborating with the team to promote further innovation and growth within the CGT bioprocessing market.

Before becoming the Executive Chairman of Repligen in September 2024, Hunt served as CEO and director for nine years. His leadership at Repligen has been marked by surpassing industry revenue growth and strengthening the company’s position as a technology leader in bioprocessing. His journey started with his role as Chief Operating Officer at Repligen in 2014 before he ascended to the CEO position.

Hunt's earlier experience includes pivotal roles at Life Technologies, where he served as the President of Bioproduction and helped develop critical areas such as Bioproduction Chromatography and Pharma Analytics. This broad background equips him with ample insight into industry trends and the competitive landscape of bioproduction and therapies.

His educational credentials include a bachelor's degree with honors in microbiology, a master's degree in biotechnology from the University of Galway, and an MBA from the Questrom School of Business at Boston University. Additionally, Hunt holds a position on the board of directors of 908 Devices Inc., where he supports innovative developments in chemical analysis technologies.

BioLife Solutions specializes in the supply of cell processing tools and services tailored for the CGT market. They pride themselves on facilitating the commercialization of new therapies by providing solutions that ensure the health and functionality of biologic materials through various stages: collection, development, storage, and distribution.

With Tony J. Hunt's strategic expertise in bioprocessing and his experience guiding companies through transformative growth phases, BioLife is well-positioned to solidify its leading role in the advanced bioproduction landscape. The company remains optimistic about the impact that Hunt will deliver as part of its committed team focused on meeting the demands of the evolving CGT sector.